Advancing Gene Therapy Programs and Strengthened Valuation Support Taysha Buy Rating and $17 Target

In a report released on April 2, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Taysha Gene Therapies, with a price target of $17.00.

Whitney Ijem has given his Buy rating due to a combination of factors tied to clinical progress, regulatory path, and valuation upside. He highlights that Taysha remains on track to finish dosing in both the REVEAL and ASPIRE studies by the second quarter of 2026, with the FDA already authorizing the start of ASPIRE in younger patients at an age‑adjusted dose.

Ijem also points to the consistently positive efficacy signals and safety profile seen so far, noting that every evaluable patient has achieved at least one developmental milestone gain, supporting the case for a pivotal program and an eventual BLA filing strategy. In addition, he updates his financial model to reflect fourth‑quarter results, a new Rett syndrome contribution, and a refreshed sum‑of‑the‑parts analysis, which together support raising the 12‑month price target to $17, underpinned by a cash runway projected to extend into 2028.

Ijem covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BioMarin Pharmaceutical, and Vertex Pharmaceuticals. According to TipRanks, Ijem has an average return of 24.2% and a 48.90% success rate on recommended stocks.

In another report released on March 24, Cantor Fitzgerald also maintained a Buy rating on the stock with a $19.00 price target.